Breaking news on lupus
Lupus Research Institute-Funded Study Points To Increased Risk For Lupus In Men published
Sat, 04 Sep 2010 01:00:00 PDT
Lupus Research Institute-funded researcher Betty Tsao, PhD, at the University of California Los Angeles has discovered that humans - males in particular - with a variant form of the immune receptor gene "Toll Like Receptor 7 (TLR7)" are at increased risk of developing the autoimmune disease systemic lupus erythematosus (lupus)...
LFA Participating In Combined Federal Campaign (CFC) To Fund Critical Research, Education Programs, Support Services And Advocacy Initiatives published
Thu, 02 Sep 2010 05:00:00 PDT
The Lupus Foundation of America (LFA) encourages current and retired federal employees to direct pledges to the Lupus Foundation of America (CFC #10566) during the Combined Federal Campaign (CFC) which kicks off this Wednesday, and runs through December 15, 2010...
Lupus Researchers Will Examine Ways To Best Apply Findings From Lupus Mouse Model To Human Lupus published
Mon, 30 Aug 2010 04:00:00 PDT
Nearly 200 lupus researchers, clinicians and representatives from government, industry, academia and nonprofit organizations involved in lupus research will gather on the campus of the National Institutes of Health to look at ways to best apply research findings from lupus mouse models to human lupus...
Study Identifies Genetic Variation Linked To Lupus In Asian Men published
Wed, 25 Aug 2010 00:00:00 PDT
Genes reside along long chains of DNA called chromosomes. UCLA researchers have found that a variation in a gene on the sex chromosome X may enhance an immune response that leads to lupus in men. Systemic lupus erythematosus (SLE) is an autoimmune disease that predominantly affects women...
Study Identifies Genetic Variation Linked To Lupus In Asian Men published
Tue, 24 Aug 2010 01:00:00 PDT
Genes reside along long chains of DNA called chromosomes. UCLA researchers have found that a variation in a gene on the sex chromosome X may enhance an immune response that leads to lupus in men. Systemic lupus erythematosus (SLE) is an autoimmune disease that predominantly affects women...
GlaxoSmithKline And Human Genome Sciences Announce FDA Priority Review Designation For Benlysta® (belimumab) published
Sat, 21 Aug 2010 02:00:00 PDT
GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE)...
Lupus Drug Benlysta® (belimumab) Priority Review Granted By FDA published
Fri, 20 Aug 2010 09:00:00 PDT
Benlysta® (belimumab), a potential treatment for systemic lupus erythematosus has been granted a priority review designation by the FDA (Food and Drug Administration, USA), which is granted to medications, that if approved, offer significant treatment advances or provide treatment when no proper therapy exists...
Human Genome Sciences And GSK Announce FDA Priority Review Designation For Benlysta(R) As A Potential Treatment For Systemic Lupus Erythematosus published
Fri, 20 Aug 2010 04:00:00 PDT
Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to BENLYSTA® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE)...
Black Women With SLE Develop Cardiovascular Disease At Early Age published
Fri, 20 Aug 2010 02:00:00 PDT
A recent study by researchers at Penn State College of Medicine found significant racial disparities in the age of systemic lupus erythematosus (SLE) patients at the time of hospital admission for cardiovascular disease (CVD) events and CVD-related death. Black women were youngest to both be admitted with CVD and to have an in-hospital death due to CVD...
New Target For Treating Autoimmunity published
Tue, 10 Aug 2010 03:00:00 PDT
Autoimmune disorders, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), occur when an individual's immune system turns on other cells in the body. Inappropriate and excessive production of the soluble immune mediators IL-17 and IL-21 have been linked to several autoimmune disorders...
New Drug Target For Immune Diseases Discovered published
Wed, 04 Aug 2010 01:00:00 PDT
Researchers from Mount Sinai School of Medicine have found a new mechanism that explains how certain immune cells are activated to create protective antibodies against infections or pathological antibodies such as those present in autoimmune diseases like lupus and rheumatoid arthritis. The research is published online in the September issue of Nature Immunology...
Researchers Uncover Biological Rationale For Why Intensive Lupus Treatment Works published
Tue, 27 Jul 2010 01:00:00 PDT
Researchers at UT Southwestern Medical Center have uncovered the biological rationale for why large doses of corticosteroids given repeatedly over several weeks may help individuals with lupus, a chronic inflammatory disease that affects more than 1 million people in the U.S...
Human Genome Sciences And Lonza Enter Commercial Manufacturing Agreement For BENLYSTA(R), A Potential New Treatment For Systemic Lupus Erythematosus published
Thu, 15 Jul 2010 05:00:00 PDT
Human Genome Sciences, Inc. (Nasdaq:HGSI) and Lonza announced an agreement for the future commercial supply of BENLYSTA® (belimumab), which is currently under regulatory review in the United States and Europe as a potential new treatment for systemic lupus erythematosus (SLE)...
New Research Uncovers Why Many With Lupus Are Resistant To Traditional Treatments published
Tue, 13 Jul 2010 02:00:00 PDT
Two immune system proteins could be the culprit behind many lupus patients' resistance to widely used steroid treatments, scientists with the Baylor Research Institute (BRI) in Dallas announced today. It is estimated that more than 5 million people suffer from lupus worldwide...
People With Lupus Denied Health Insurance Due To Pre-Existing Condition May Be Able To Obtain Coverage Through Health Care Reform Law Plan published
Wed, 07 Jul 2010 03:00:00 PDT
President Obama signed the Health Care Reform package in to law in March 2010, which will extend insurance coverage to as many as 32 million Americans who currently do not have health insurance, as well as provide much-needed protections for people with lupus and other chronic conditions...
Research Presented At The 9th International Lupus Congress Provides Hope And Encouragement For The Future Treatment And Management Of Lupus published
Sun, 27 Jun 2010 01:00:00 PDT
Research presented during the 9th International Lupus Congress held in Vancouver, Canada from June 24-27, 2010 should give hope and encouragement for the future of the treatment and management of lupus to the 1.5 million Americans and 5 million people worldwide living with lupus...
Oxidative And Nitrosative Stress Contribute To Lupus Disease Activity published
Fri, 25 Jun 2010 02:00:00 PDT
University of Texas Medical Branch researchers have uncovered an association between free radical-mediated reactions and the severity and progression of system lupus erythematosus (SLE). Higher levels of oxidative and nitrosative stress markers were found in SLE patients with greater disease activity suggesting a causal relationship...
Clinical Differences In Systemic Lupus Erythmatosus Patients May Be Affected By Genealogy published
Mon, 21 Jun 2010 01:00:00 PDT
The effects of Systemic Lupus Erythematosus (SLE) may differ based on the individual patient's genealogical heritage, according to results of a new study presented at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. In particular, the study reinforced differences in SLE phenotype found between Northern and Southern European subpopulations...
Chinese Systemic Lupus Erythematosus Data Reveal Differences In Epidemiology Across Continents published
Mon, 21 Jun 2010 01:00:00 PDT
The Chinese Systemic Lupus Erythematosus (SLE) Treatment and Research Group (CSTAR) announced interim epidemiological information on SLE patients in China at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. Robust data on SLE patients has been scarce to date; but now CSTAR provides the first online registry of this magnitude in China...
Rheumatoid Arthritis And SLE Negatively Affect The Sex Lives Of Patients published
Mon, 21 Jun 2010 00:00:00 PDT
Systemic Lupus Erythematosus (SLE) patients from Brazil and Rheumatoid Arthritis (RA) patients from France report that their rheumatic conditions negatively affect their emotional relationships and sex lives, according to research presented at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy...
The LFA To Report On The Latest News From The International Lupus Congress published
Fri, 18 Jun 2010 04:00:00 PDT
Representatives and staff from the Lupus Foundation of America (LFA) are headed to the International Lupus Congress, which will be held from June 24-27 in Vancouver, Canada. This triennial meeting brings together physicians and researchers to share the latest developments in lupus...
NATURE Publishes New Dynavax Findings On Novel Role Of TLRs In Lupus published
Thu, 17 Jun 2010 04:00:00 PDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported in NATURE new data that may explain the resistance of lupus patients to glucocorticoid treatment. In the June 16, 2010 issue of NATURE, Dynavax scientists show that activation of cells of the innate immune system by two key receptors, TLR7 and TLR9, can cause glucocorticoid resistance in lupus patients...
New Data Shows Epratuzumab Provided Significant Efficacy For Patients With Moderate To Severe Systemic Lupus Erythematosus published
Thu, 17 Jun 2010 03:00:00 PDT
UCB (EURONEXT: UCB) and Immunomedics Inc. (NASDAQ:IMMU) announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE)...
New Data Presented From EMBLEM™ Study For Pipeline Drug Epratuzumab For Patients Suffering From Moderate To Severe Systemic Lupus Erythematosus published
Thu, 17 Jun 2010 02:00:00 PDT
UCB (Euronext: UCB) and Immunomedics, Inc. (Nasdaq: IMMU) announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE)...
Lupus Foundation Of America Says Results Of Latest Study Of CellCept Provide Encouragement And Hope For People With Lupus Nephritis published
Sun, 06 Jun 2010 00:00:00 PDT
The Lupus Foundation of America praised the results of a new long-term study for the treatment of lupus nephritis (lupus-related kidney disease) which demonstrated superiority of CellCept® (mycophenolate mofetil or MMF) to azathioprine (standard care) as a long-term treatment for lupus nephritis...
)
|
|
